Blog
RSS FeedPosted by Michael Wonder on 28 Jan 2022
Glaucoma drug Vyzulta, psoriasis remedy Skilarence win insurance benefit
28 January 2022 - The government granted health insurance benefits for Bausch Health Korea’s glaucoma treatment Vyzulta (latanoprostene bunod) and ...
Posted by Michael Wonder on 17 Jan 2022
Keytruda reimbursement boosts MSD’s R&D of follow-up drug
17 January 2022 - The government’s recognition of MSD’s Keytruda (pembrolizumab) for reimbursement as the first-line therapy for lung cancer ...
Posted by Michael Wonder on 17 Jan 2022
$421,000 cancer drug Kymriah becomes eligible for reimbursement
14 January 2022 - Novartis’ breakthrough cancer treatment Kymriah (ingredient: tisagenlecleucel), which costs over 500 million won (US$421,000), has become ...
Posted by Michael Wonder on 25 Nov 2021
Tagrisso, Opdivo fail to get broader reimbursement
25 November 2021 - AstraZeneca Korea’s non-small-cell lung cancer treatment Tagrisso (osimertinib) and Ono Pharma Korea’s immunotherapy Opdivo (nivolumab) failed ...
Posted by Michael Wonder on 10 Nov 2021
KRPIA raises concern over HIRA’s cost effectiveness evaluation plan
10 November 2021 - Korea Research-based Pharma Industry Association (KRPIA) expressed concerns over HIRA's plan of evaluating a drug’s cost ...
Posted by Michael Wonder on 14 Oct 2021
Drug pricing tug of war expected over CAR-T therapy Kymriah
14 October 2021 - The world’s first CAR-T therapy, Kymriah (tisagenlecleucel), passed the review of a panel at the Health ...
Posted by Michael Wonder on 11 Oct 2021
Takeda's ovarian cancer drug Zejula gets expanded insurance benefit
1 October 2021 - Takeda Korea said its ovarian cancer treatment Zejula would receive expanded health insurance coverage as maintenance ...
Posted by Michael Wonder on 28 Sep 2021
A review of utility measurement methods used in pharmacoeconomic submissions to HIRA in South Korea: methodological consistency and areas for improvement
28 September 2021 - This study, which was conducted as part of a project for revision of the pharmacoeconomic ...
Posted by Michael Wonder on 27 Sep 2021
Will price of Avastin, staple in anti-cancer therapy, go down?
27 September 2021 - Avastin (bevacizumab), a vascular endothelial growth factor (VEGF) inhibitor, is almost a staple in anticancer treatment ...
Posted by Michael Wonder on 19 Sep 2021
Manufacturers’ perceptions of the decision-making process for new drug reimbursement in South Korea
17 September 2021 - This study aimed to evaluate manufacturers’ perceptions of the decision-making process for new drug reimbursement and to ...
Posted by Michael Wonder on 09 Sep 2021
Insurance benefits for Pfizer’s heart drug Vyndamax uncertain
9 September 2021 - Pfizer’s Vyndamax (tafamidis), a treatment for transthyretin amyloid cardiomyopathy, got in the European Society of Cardiology’s ...
Posted by Michael Wonder on 07 Sep 2021
Reimbursement uncertain for Piqray targeting PIK3CA mutation in breast cancer
7 September 2021 - The first and only targeted therapy to treat hormone receptor positive and human epidermal growth factor ...
Posted by Michael Wonder on 03 Sep 2021
Acute myeloid leukaemia drug Xospata nears getting insurance benefits
3 September 2021 - Astellas Korea’s Xospata 40mg (gilteritinib fumarate), a treatment for acute myeloid leukaemia, has taken a step ...
Posted by Michael Wonder on 02 Sep 2021
Pfizer’s acromegaly treatment receives reimbursement
2 September 2021 - Pfizer Korea said Thursday that the Ministry of Health and Welfare would begin to reimburse Somavert, ...
Posted by Michael Wonder on 02 Sep 2021
CAR-T therapy Kymriah fails to get insurance benefits
2 September 2021 - The first CAR-T therapy, Kymriah (ingredient: tisagenlecleucel), failed to pass the review of a panel at ...